Albuterol market share
21%
+4-5pp YoY
Albuterol market share increased to 21% as per IQVIA MAT week ended 27 Dec 2024, up from ~16-17% earlier.
CIPLA
Healthcare
17 Jan 2025
Cipla Ltd — Q3 FY25
Cipla reported Q3 FY25 revenue of INR 7,073 crore (+8% YoY) and EBITDA margin of 28% (+184bps YoY), driven by strong India (10% growth), South Africa (21% ZAR), and EMEU (20% USD) performance.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla reported Q3 FY25 revenue of INR 7,073 crore (+8% YoY) and EBITDA margin of 28% (+184bps YoY), driven by strong India (10% growth), South Africa (21% ZAR), and EMEU (20% USD) performance. US revenue was $226M, impacted by lanreotide supply disruption, but Albuterol market share reached 21%. Management reiterated FY26 top-line growth guidance and expects EBITDA for FY25 to exceed the 24.5%-25.5% range. Key catalysts include generic Advair launch in H1 FY26 and Abraxane in H2 FY26 from the now-cleared Goa facility. Risks include regulatory delays at Bengaluru and MDI facilities, and potential US tariff impacts, though US manufacturing de-risks some exposure.
सिप्ला ने तीसरी तिमाही में 7,073 करोड़ रुपये की कमाई की, जो पिछले साल से 8% ज्यादा है। कंपनी का मुनाफा मार्जिन 28% रहा, जो पिछले साल से बेहतर है। भारत में 10%, दक्षिण अफ्रीका में 21% और यूरोप-मध्य पूर्व में 20% की बढ़ोतरी हुई। अमेरिका में कमाई 226 मिलियन डॉलर रही, जो एक दवा की आपूर्ति में रुकावट के कारण कम हुई, लेकिन अल्ब्युटेरोल दवा का बाजार हिस्सा 21% पहुंच गया। कंपनी ने अगले साल कमाई बढ़ने का भरोसा दिया है। नई दवाएं जैसे एडवायर और एब्राक्सेन अगले साल लॉन्च होंगी। जोखिमों में बेंगलुरु और एमडीआई कारखानों में देरी और अमेरिकी टैरिफ शामिल हैं, लेकिन अमेरिका में उत्पादन से कुछ सुरक्षा है।
Key Numbers
One India growth
10%
+10% YoY
India business grew 10% YoY despite seasonal headwinds in acute category, with chronic mix improving to 61.5%.
US revenue
$226M
flat YoY (adjusted for lanreotide disruption would be growth)
US quarterly revenue was $226M; lanreotide supply issues impacted growth, expected to normalize by end of Q4.
South Africa private market rank
#2
improved from #3
Cipla's South Africa private market now ranks #2, with prescription business maintaining #1 position as per MAT Nov 2024.
What Changed vs Last Quarter
NEW
FY26 top-line growth guidance retained
Management reiterated guidance to grow top line in FY26, with further profitability guidance to be provided after budget finalization.
NEW
Abraxane launch in H2 FY26
Abraxane launch expected from Goa facility post-approval, likely in back end of second half FY26 (Q4 FY26).
UPDATED
Generic Advair launch in late H1 FY26
Cipla plans to launch generic Advair from its US facility in late first half of FY26, with de-risking progressing as expected.
UPDATED
FY25 EBITDA margin to exceed guidance
EBITDA for FY25 is trending higher than earlier guidance of 24.5%-25.5%, with Q3 margin at 28% but not sustainable.
DROPPED
Lanreotide supply issues to resolve by end of Q3, recovery in Q4
Supply challenges expected to be resolved by end of Q3, with sharp recovery in lanreotide franchise from Q4 FY25.
DROPPED
One India to outpace market growth on full-year basis
Management expects India business to revert to growth trajectory with respiratory uptick in Q3 and outpace market growth for the full year.
NEW RISK
Regulatory delays at Bengaluru and MDI facilities
US FDA issued Form 483 observations at Virgonagar (Bengaluru) and MDI facilities; official classification awaited, potentially delaying product approvals.
NEW RISK
US tariff policy uncertainty
Potential US tariffs on pharmaceutical imports could impact margins; management noted de-risking via US facilities but awaits policy clarity.
NEW RISK
Generic Revlimid revenue decline
Revlimid revenue is flat sequentially and expected to decline as competition increases; new launches may only partially offset the reduction.
RISK GONE
Goa facility FDA classification uncertainty
Goa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.
RISK GONE
US generic pricing erosion
Blended US price erosion of ~10% YoY, with potential for further pressure from new competition in Albuterol and other products.
RISK GONE
India acute season weakness
Slow seasonal growth in acute category, especially anti-infectives, impacted India business; recovery dependent on respiratory season.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q2 FY25, Q3 FY24
Goa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Filed generic Symbicort and one other inhalation asset; second site transfer to be added before approval.
Mentioned in Q1 FY24, Q2 FY24
Albuterol share is dependent on which variant the market buys; recovery to prior highs is not fully in Cipla's control.
Mentioned in Q1 FY24, Q3 FY24
Goa facility due for re-inspection; delay or adverse outcome could further delay Abraxane launch.
Mentioned in Q1 FY25, Q2 FY25
Supply issues at partner site will reduce Q3 lanreotide sales significantly; recovery depends on partner's production ramp-up.
Management Guidance
FY26 top-line growth guidance retained
Management reiterated guidance to grow top line in FY26, with further profitability guidance to be provided after budget finalization.
Management guidance revenueGeneric Advair launch in late H1 FY26
Cipla plans to launch generic Advair from its US facility in late first half of FY26, with de-risking progressing as expected.
Management guidance growthAbraxane launch in H2 FY26
Abraxane launch expected from Goa facility post-approval, likely in back end of second half FY26 (Q4 FY26).
Management guidance growthFY25 EBITDA margin to exceed guidance
EBITDA for FY25 is trending higher than earlier guidance of 24.5%-25.5%, with Q3 margin at 28% but not sustainable.
Management guidance marginsKey Risks
Regulatory delays at Bengaluru and MDI facilities
US FDA issued Form 483 observations at Virgonagar (Bengaluru) and MDI facilities; official classification awaited, potentially delaying product approvals.
high · management_commentaryLanreotide supply disruption recovery timeline
Lanreotide supply issues impacted US revenue; management expects normalization by end of Q4, but full capacity recovery may extend into Q1 FY26.
medium · analyst_questionUS tariff policy uncertainty
Potential US tariffs on pharmaceutical imports could impact margins; management noted de-risking via US facilities but awaits policy clarity.
medium · analyst_questionGeneric Revlimid revenue decline
Revlimid revenue is flat sequentially and expected to decline as competition increases; new launches may only partially offset the reduction.
high · data_observationNotable Quotes
We believe that if we were to add a fuller basis of Abraxane and a fuller basis of Advair and a fuller basis of the partnered inhalation asset, we believe that this is quite meaningful in the ability to offset share of the generic Revlimid reduction.
The EBITDA margin stood at impressive 28% for the quarter, up by 184 basis points YOY and 138 basis points QOQ.
I don't think Cipla can do 28% margins, EBITDA margins. And that is what I had mentioned because the question was with respect to quarter, whether you'd be able to do 28% EBITDA consistently. And I had said, 'No, that's not a sustainable margin profile for us.'
Frequently Asked Questions
What was Cipla's revenue in Q3 FY25?
Cipla reported revenue of ₹7,073 Cr in Q3 FY25, representing a +8% change compared to the same quarter last year.
What guidance did Cipla management give for FY26?
FY26 top-line growth guidance retained: Management reiterated guidance to grow top line in FY26, with further profitability guidance to be provided after budget finalization. Generic Advair launch in late H1 FY26: Cipla plans to launch generic Advair from its US facility in late first half of FY26, with de-risking progressing as expected. Abraxane launch in H2 FY26: Abraxane launch expected from Goa facility post-approval, likely in back end of second half FY26 (Q4 FY26). FY25 EBITDA margin to exceed guidance: EBITDA for FY25 is trending higher than earlier guidance of 24.5%-25.5%, with Q3 margin at 28% but not sustainable.
What are the key risks for Cipla in FY26?
Key risks include Regulatory delays at Bengaluru and MDI facilities — US FDA issued Form 483 observations at Virgonagar (Bengaluru) and MDI facilities; official classification awaited, potentially delaying product approvals.; Lanreotide supply disruption recovery timeline — Lanreotide supply issues impacted US revenue; management expects normalization by end of Q4, but full capacity recovery may extend into Q1 FY26.; US tariff policy uncertainty — Potential US tariffs on pharmaceutical imports could impact margins; management noted de-risking via US facilities but awaits policy clarity.; Generic Revlimid revenue decline — Revlimid revenue is flat sequentially and expected to decline as competition increases; new launches may only partially offset the reduction..
Did Cipla meet its previous quarter's guidance?
Of 1 tracked promise, management 0 met, 0 close, 1 missed.
Where can I read the full Cipla Q3 FY25 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.